Replimune Group, Inc.
REPL
Rank in Stocks
#5739
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering... Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Share Price
$22.26
Last synced: 2026-11-09
Market Cap
$2.11B
Change (1 day)
2.96%
Change (1 year)
146.24%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Replimune Group, Inc. (REPL)
Category
Healthcare
Number of shares outstanding for Replimune Group, Inc. (REPL)
Number of shares outstanding as of September 2026: 105.18M
According to Replimune Group, Inc.'s latest financial reports, its current number of shares outstanding is 105.18M. At the end of 2025 the company had 80.56M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Replimune Group, Inc. (REPL) from 2017 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 105.18M | 30.55% |
| 2025 | 80.56M | 21.02% |
| 2024 | 66.57M | 14.36% |
| 2023 | 58.21M | 11.49% |
| 2022 | 52.21M | 12.89% |
| 2021 | 46.25M | 34.99% |
| 2020 | 34.26M | 47.69% |
| 2019 | 23.20M | -24.77% |
| 2018 | 30.84M | 43.39% |
| 2017 | 21.51M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 141.02% |
US
|
|
| 401.00M | 281.27% |
US
|
|
| 478.91M | 355.34% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | -40.35% |
NL
|
Questions about Replimune Group, Inc.'s number of shares outstanding
What is Replimune Group, Inc.'s number of shares outstanding?
Replimune Group, Inc.'s number of shares outstanding is 105.18M, as of Sep 2026.
What was Replimune Group, Inc.'s number of shares outstanding in 2025?
In 2025, Replimune Group, Inc.'s number of shares outstanding was 80.56M, 21.02% more than in 2024 (66.57M).
How has Replimune Group, Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, Replimune Group, Inc.'s number of shares outstanding went from 34.26M to 80.56M, an average growth of 18.65% a year.